Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 1,741–1,750 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1741

    Medicine slug
    daridorexant
    Medicine name
    Daridorexant
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3a2d1503-b816-40c9-9fac-7e03c5a3bcef (opens source in a new tab)

      Daridorexant label

      Version not recorded · Effective date not recorded

      P-gp = P-glycoprotein;
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3a2d1503-b816-40c9-9fac-7e03c5a3bcef (opens source in a new tab)

      Daridorexant label

      Version not recorded · Effective date not recorded

      P-gp = P-glycoprotein;

  2. Projected row 1742

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP1A2
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Effects of Darifenacin on Other Drugs In Vitro Studies: Based on in vitro human microsomal studies, darifenacin extended-release tablet is not expected to inhibit CYP1A2 or CYP2C9 at clinically relevant concentrations.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Effects of Darifenacin on Other Drugs In Vitro Studies: Based on in vitro human microsomal studies, darifenacin extended-release tablet is not expected to inhibit CYP1A2 or CYP2C9 at clinically relevant concentrations.

  3. Projected row 1743

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP2C9
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Effects of Darifenacin on Other Drugs In Vitro Studies: Based on in vitro human microsomal studies, darifenacin extended-release tablet is not expected to inhibit CYP1A2 or CYP2C9 at clinically relevant concentrations.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Effects of Darifenacin on Other Drugs In Vitro Studies: Based on in vitro human microsomal studies, darifenacin extended-release tablet is not expected to inhibit CYP1A2 or CYP2C9 at clinically relevant concentrations.

  4. Projected row 1744

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP2D6
    Role
    INHIBITOR
    Asserted sentences
    3
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP2D6 Inhibitors: Darifenacin exposure following 30 mg once daily at steady-state was 33% higher in the presence of the potent CYP2D6 inhibitor paroxetine 20 mg [see Drug Interactions ( 7.2 )] .
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      The 75 mg darifenacin extended-release tablets dose was chosen because this achieves exposure similar to that observed in CYP2D6 poor metabolizers administered the highest recommended dose (15 mg) of darifenacin in the presence of a potent CYP3A4 inhibitor.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP2D6 Inhibitors: Darifenacin exposure following 30 mg once daily at steady-state was 33% higher in the presence of the potent CYP2D6 inhibitor paroxetine 20 mg [see Drug Interactions ( 7.2 )] .

  5. Projected row 1745

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP2D6
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    12
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Figure 1 Mean (SD) Steady-State Darifenacin Plasma Concentration-Time Profiles for Darifenacin Extended-Release Tablets 7.5 mg and 15 mg in Healthy Volunteers Including Both CYP2D6 EMs and PMs* A summary of mean (standard deviation, SD) steady-state pharmacokinetic parameters of darifenacin 7.5 mg and 15 mg extended-release tablets in EMs and PMs of CYP2D6 is provided in Table 3.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Variability in Metabolism A subset of individuals (approximately 7% Caucasians and 2% African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs.
    4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Individuals with normal CYP2D6 activity are referred to as extensive metabolizers (EMs).
    5. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Drug-Drug Interactions Effects of Other Drugs on Darifenacin Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
    6. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      In Vivo Studies: The potential for clinical doses of darifenacin extended-release tablets to act as inhibitors of CYP2D6 or CYP3A4 substrates was investigated in specific drug interaction studies.
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Figure 1 Mean (SD) Steady-State Darifenacin Plasma Concentration-Time Profiles for Darifenacin Extended-Release Tablets 7.5 mg and 15 mg in Healthy Volunteers Including Both CYP2D6 EMs and PMs* A summary of mean (standard deviation, SD) steady-state pharmacokinetic parameters of darifenacin 7.5 mg and 15 mg extended-release tablets in EMs and PMs of CYP2D6 is provided in Table 3.
    8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4.
    9. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Variability in Metabolism A subset of individuals (approximately 7% Caucasians and 2% African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs.
    10. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Individuals with normal CYP2D6 activity are referred to as extensive metabolizers (EMs).
    11. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Drug-Drug Interactions Effects of Other Drugs on Darifenacin Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
    12. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      In Vivo Studies: The potential for clinical doses of darifenacin extended-release tablets to act as inhibitors of CYP2D6 or CYP3A4 substrates was investigated in specific drug interaction studies.

  6. Projected row 1746

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP2D6
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP2D6 Substrates: The mean C max and AUC of imipramine, a CYP2D6 substrate, were increased by 57% and 70%, respectively, in the presence of steady-state darifenacin 30 mg once daily.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP2D6 Substrates: The mean C max and AUC of imipramine, a CYP2D6 substrate, were increased by 57% and 70%, respectively, in the presence of steady-state darifenacin 30 mg once daily.

  7. Projected row 1747

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    7
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP3A4 Inhibitors: In a drug interaction study, when a 7.5 mg once daily dose of darifenacin extended-release tablet was given to steady-state and co-administered with the potent CYP3A4 inhibitor ketoconazole 400 mg, mean darifenacin Cmax increased to 11.2 ng/mL for EMs (n = 10) and 55.4 ng/mL for one PM subject (n = 1).
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      The mean C max and AUC of darifenacin following 30 mg once daily dosing at steady-state were 128% and 95% higher, respectively, in the presence of a moderate CYP3A4 inhibitor, erythromycin.
    3. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Co-administration of fluconazole, a moderate CYP3A4 inhibitor and darifenacin 30 mg once daily at steady-state increased darifenacin C max and AUC by 88% and 84%, respectively [see Drug Interactions ( 7.1 )] .
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      The 75 mg darifenacin extended-release tablets dose was chosen because this achieves exposure similar to that observed in CYP2D6 poor metabolizers administered the highest recommended dose (15 mg) of darifenacin in the presence of a potent CYP3A4 inhibitor.
    5. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP3A4 Inhibitors: In a drug interaction study, when a 7.5 mg once daily dose of darifenacin extended-release tablet was given to steady-state and co-administered with the potent CYP3A4 inhibitor ketoconazole 400 mg, mean darifenacin Cmax increased to 11.2 ng/mL for EMs (n = 10) and 55.4 ng/mL for one PM subject (n = 1).
    6. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      The mean C max and AUC of darifenacin following 30 mg once daily dosing at steady-state were 128% and 95% higher, respectively, in the presence of a moderate CYP3A4 inhibitor, erythromycin.
    7. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Co-administration of fluconazole, a moderate CYP3A4 inhibitor and darifenacin 30 mg once daily at steady-state increased darifenacin C max and AUC by 88% and 84%, respectively [see Drug Interactions ( 7.1 )] .

  8. Projected row 1748

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    10
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      The metabolism of darifenacin in PMs will be principally mediated via CYP3A4.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Drug-Drug Interactions Effects of Other Drugs on Darifenacin Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
    4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Therefore, inducers of CYP3A4 or inhibitors of either of these enzymes may alter darifenacin pharmacokinetics [see Drug Interactions ( 7 )] .
    5. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      In Vivo Studies: The potential for clinical doses of darifenacin extended-release tablets to act as inhibitors of CYP2D6 or CYP3A4 substrates was investigated in specific drug interaction studies.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4.
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      The metabolism of darifenacin in PMs will be principally mediated via CYP3A4.
    8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Drug-Drug Interactions Effects of Other Drugs on Darifenacin Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
    9. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      Therefore, inducers of CYP3A4 or inhibitors of either of these enzymes may alter darifenacin pharmacokinetics [see Drug Interactions ( 7 )] .
    10. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      In Vivo Studies: The potential for clinical doses of darifenacin extended-release tablets to act as inhibitors of CYP2D6 or CYP3A4 substrates was investigated in specific drug interaction studies.

  9. Projected row 1749

    Medicine slug
    darifenacin
    Medicine name
    Darifenacin
    Enzyme or transporter
    CYP3A4
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP3A4 Substrates: Darifenacin (30 mg daily) co-administered with a single oral dose of midazolam 7.5 mg resulted in a 17% increase in midazolam exposure.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:6e8470d1-c3e6-4644-b70a-aa47ddf79676 (opens source in a new tab)

      Darifenacin label

      Version not recorded · Effective date not recorded

      CYP3A4 Substrates: Darifenacin (30 mg daily) co-administered with a single oral dose of midazolam 7.5 mg resulted in a 17% increase in midazolam exposure.

  10. Projected row 1750

    Medicine slug
    darolutamide
    Medicine name
    Darolutamide
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:1a7cb212-56e4-4b9d-a73d-bfee7fe4735e (opens source in a new tab)

      Darolutamide label

      Version not recorded · Effective date not recorded

      BCRP, OATP1B1 and OATP1B3 Substrates Concomitant use of darolutamide increased the mean AUC and C max of rosuvastatin (BCRP, OATP1B1 and OATP1B3 substrate) by approximately 5-fold.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:1a7cb212-56e4-4b9d-a73d-bfee7fe4735e (opens source in a new tab)

      Darolutamide label

      Version not recorded · Effective date not recorded

      BCRP, OATP1B1 and OATP1B3 Substrates Concomitant use of darolutamide increased the mean AUC and C max of rosuvastatin (BCRP, OATP1B1 and OATP1B3 substrate) by approximately 5-fold.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=1740

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy